与FLT3抑制相关的Sweet综合征。 - Suppr

Sweet's syndrome associated with FLT3 inhibition.

作者信息

Seervai Riyad N H, Munoz Elena Paz, Freeman S Caleb, Swords Ronan I, White Kevin P, Keller Jesse J

机构信息

Department of Dermatology, Oregon Health & Science University, Portland, Oregon.

Division of Hematology/Oncology, Department of Medicine, Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon.

出版信息

JAAD Case Rep. 2024 Sep 30;54:89-92. doi: 10.1016/j.jdcr.2024.09.013. eCollection 2024 Dec.

DOI:10.1016/j.jdcr.2024.09.013

PMID:39687070

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11646748/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/da75/11646748/5e798ee5ee62/gr1.jpg

相似文献

Sweet's syndrome associated with FLT3 inhibition.

JAAD Case Rep. 2024 Sep 30;54:89-92. doi: 10.1016/j.jdcr.2024.09.013. eCollection 2024 Dec.

Sweet's syndrome in a granulocytopenic patient with acute myeloid leukemia on FLT3 inhibitor.

J Community Hosp Intern Med Perspect. 2020 Jun 14;10(3):275-278. doi: 10.1080/20009666.2020.1766818.

Proton pump inhibitor-induced Sweet's syndrome: report of acute febrile neutrophilic dermatosis in a woman with recurrent breast cancer.

Dermatol Pract Concept. 2015 Apr 30;5(2):113-9. doi: 10.5826/dpc.0502a23. eCollection 2015 Apr.

Sweet's syndrome--a comprehensive review of an acute febrile neutrophilic dermatosis.

Orphanet J Rare Dis. 2007 Jul 26;2:34. doi: 10.1186/1750-1172-2-34.

Trimethoprim-sulfamethoxazole-associated acute febrile neutrophilic dermatosis: case report and review of drug-induced Sweet's syndrome.

J Am Acad Dermatol. 1996 May;34(5 Pt 2):918-23. doi: 10.1016/s0190-9622(96)90080-8.

Acute febrile neutrophilic dermatosis (Sweet's syndrome).

Curr Opin Hematol. 2013 Jan;20(1):26-35. doi: 10.1097/MOH.0b013e32835ad132.

Association of Sweet's Syndrome and Behçet's Disease: Is It Possible? A Case Report.

Eur J Case Rep Intern Med. 2023 Sep 19;10(10):004073. doi: 10.12890/2023_004073. eCollection 2023.

Sweet's syndrome revisited: a review of disease concepts.

Int J Dermatol. 2003 Oct;42(10):761-78. doi: 10.1046/j.1365-4362.2003.01891.x.

Sweet's syndrome: a cutaneous harbinger of ovarian carcinoma.

J Gynecol Oncol. 2012 Oct;23(4):288-90. doi: 10.3802/jgo.2012.23.4.288. Epub 2012 Sep 19.

Sweet's syndrome triggered by ultraviolet light.

Photodiagnosis Photodyn Ther. 2021 Jun;34:102258. doi: 10.1016/j.pdpdt.2021.102258. Epub 2021 Mar 15.

本文引用的文献

Treatment of older adults with FLT3-mutated AML: Emerging paradigms and the role of frontline FLT3 inhibitors.

Blood Cancer J. 2023 Sep 11;13(1):142. doi: 10.1038/s41408-023-00911-w.

Gilteritinib: A Novel FLT3 Inhibitor for Relapsed/Refractory Acute Myeloid Leukemia.

J Adv Pract Oncol. 2020 Jan-Feb;11(1):104-108. doi: 10.6004/jadpro.2020.11.1.7. Epub 2020 Jan 1.

First-in-Human Phase I Study of Iadademstat (ORY-1001): A First-in-Class Lysine-Specific Histone Demethylase 1A Inhibitor, in Relapsed or Refractory Acute Myeloid Leukemia.

J Clin Oncol. 2020 Dec 20;38(36):4260-4273. doi: 10.1200/JCO.19.03250. Epub 2020 Oct 14.

Gilteritinib or Chemotherapy for Relapsed or Refractory -Mutated AML.

N Engl J Med. 2019 Oct 31;381(18):1728-1740. doi: 10.1056/NEJMoa1902688.

Sweet syndrome in patients with and without malignancy: A retrospective analysis of 83 patients from a tertiary academic referral center.

J Am Acad Dermatol. 2018 Feb;78(2):303-309.e4. doi: 10.1016/j.jaad.2017.09.013. Epub 2017 Oct 26.

FLT3 Inhibitor-Associated Neutrophilic Dermatoses.

JAMA Dermatol. 2016 Apr;152(4):480-2. doi: 10.1001/jamadermatol.2015.6121.

FLT3 inhibitor-induced neutrophilic dermatosis.

Blood. 2013 Jul 11;122(2):239-42. doi: 10.1182/blood-2013-01-478172. Epub 2013 May 17.

Sweet syndrome-like neutrophilic infiltrate as initial presentation of acute myelogenous leukemia.

Am J Dermatopathol. 2014 Oct;36(10):e167-70. doi: 10.1097/DAD.0b013e3182897b0a.

Trimethoprim-sulfamethoxazole-associated acute febrile neutrophilic dermatosis: case report and review of drug-induced Sweet's syndrome.

J Am Acad Dermatol. 1996 May;34(5 Pt 2):918-23. doi: 10.1016/s0190-9622(96)90080-8.

A method for estimating the probability of adverse drug reactions.

Clin Pharmacol Ther. 1981 Aug;30(2):239-45. doi: 10.1038/clpt.1981.154.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Sweet's syndrome associated with FLT3 inhibition.

JAAD Case Rep. 2024 Sep 30;54:89-92. doi: 10.1016/j.jdcr.2024.09.013. eCollection 2024 Dec.

Sweet's syndrome in a granulocytopenic patient with acute myeloid leukemia on FLT3 inhibitor.

J Community Hosp Intern Med Perspect. 2020 Jun 14;10(3):275-278. doi: 10.1080/20009666.2020.1766818.

Proton pump inhibitor-induced Sweet's syndrome: report of acute febrile neutrophilic dermatosis in a woman with recurrent breast cancer.

Dermatol Pract Concept. 2015 Apr 30;5(2):113-9. doi: 10.5826/dpc.0502a23. eCollection 2015 Apr.

Sweet's syndrome--a comprehensive review of an acute febrile neutrophilic dermatosis.

Orphanet J Rare Dis. 2007 Jul 26;2:34. doi: 10.1186/1750-1172-2-34.

Trimethoprim-sulfamethoxazole-associated acute febrile neutrophilic dermatosis: case report and review of drug-induced Sweet's syndrome.

J Am Acad Dermatol. 1996 May;34(5 Pt 2):918-23. doi: 10.1016/s0190-9622(96)90080-8.

Acute febrile neutrophilic dermatosis (Sweet's syndrome).

Curr Opin Hematol. 2013 Jan;20(1):26-35. doi: 10.1097/MOH.0b013e32835ad132.

Association of Sweet's Syndrome and Behçet's Disease: Is It Possible? A Case Report.

Eur J Case Rep Intern Med. 2023 Sep 19;10(10):004073. doi: 10.12890/2023_004073. eCollection 2023.

Sweet's syndrome revisited: a review of disease concepts.

Int J Dermatol. 2003 Oct;42(10):761-78. doi: 10.1046/j.1365-4362.2003.01891.x.

Sweet's syndrome: a cutaneous harbinger of ovarian carcinoma.

J Gynecol Oncol. 2012 Oct;23(4):288-90. doi: 10.3802/jgo.2012.23.4.288. Epub 2012 Sep 19.

Sweet's syndrome triggered by ultraviolet light.

Photodiagnosis Photodyn Ther. 2021 Jun;34:102258. doi: 10.1016/j.pdpdt.2021.102258. Epub 2021 Mar 15.

本文引用的文献

Treatment of older adults with FLT3-mutated AML: Emerging paradigms and the role of frontline FLT3 inhibitors.

Blood Cancer J. 2023 Sep 11;13(1):142. doi: 10.1038/s41408-023-00911-w.

Gilteritinib: A Novel FLT3 Inhibitor for Relapsed/Refractory Acute Myeloid Leukemia.

J Adv Pract Oncol. 2020 Jan-Feb;11(1):104-108. doi: 10.6004/jadpro.2020.11.1.7. Epub 2020 Jan 1.

First-in-Human Phase I Study of Iadademstat (ORY-1001): A First-in-Class Lysine-Specific Histone Demethylase 1A Inhibitor, in Relapsed or Refractory Acute Myeloid Leukemia.

J Clin Oncol. 2020 Dec 20;38(36):4260-4273. doi: 10.1200/JCO.19.03250. Epub 2020 Oct 14.

Gilteritinib or Chemotherapy for Relapsed or Refractory -Mutated AML.

N Engl J Med. 2019 Oct 31;381(18):1728-1740. doi: 10.1056/NEJMoa1902688.

Sweet syndrome in patients with and without malignancy: A retrospective analysis of 83 patients from a tertiary academic referral center.

J Am Acad Dermatol. 2018 Feb;78(2):303-309.e4. doi: 10.1016/j.jaad.2017.09.013. Epub 2017 Oct 26.

FLT3 Inhibitor-Associated Neutrophilic Dermatoses.

JAMA Dermatol. 2016 Apr;152(4):480-2. doi: 10.1001/jamadermatol.2015.6121.

FLT3 inhibitor-induced neutrophilic dermatosis.

Blood. 2013 Jul 11;122(2):239-42. doi: 10.1182/blood-2013-01-478172. Epub 2013 May 17.

Sweet syndrome-like neutrophilic infiltrate as initial presentation of acute myelogenous leukemia.

Am J Dermatopathol. 2014 Oct;36(10):e167-70. doi: 10.1097/DAD.0b013e3182897b0a.

Trimethoprim-sulfamethoxazole-associated acute febrile neutrophilic dermatosis: case report and review of drug-induced Sweet's syndrome.

J Am Acad Dermatol. 1996 May;34(5 Pt 2):918-23. doi: 10.1016/s0190-9622(96)90080-8.

A method for estimating the probability of adverse drug reactions.

Clin Pharmacol Ther. 1981 Aug;30(2):239-45. doi: 10.1038/clpt.1981.154.

Sweet's syndrome associated with FLT3 inhibition.

作者信息

机构信息

出版信息

相似文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

本文引用的文献